Visit Quibim at the American Society of Clinical Oncology Annual Meeting!
Booth 27149
At Quibim we are redefining the future of oncology through our innovative AI-based diagnostic and predictive imaging biomarkers.
Let’s explore how we can partner to accelerate the next wave of medical innovation.
Advancing science through evidence
Survival, neurotoxicity and response prediction in CAR-T
Predicting survival (OS and PFS), neurotoxicity and treatment response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.
End-to-end automated PSMA PET solution
Streamlining reader workflows and reducing inter-reader variability in clinical trials with our AI-powered solution for automatic whole-body lesions segmentation and quantification of PSMA PET.
AI-supported RECIST
Quibim is part of the multi-stakeholder working group convened by Friends of Cancer Research (FoCR) to evaluate the current landscape of AI-enabled tumor assessment tools and define a stepwise roadmap for their integration into clinical trials.
Risk of relapse in localized colon cancer
AI-based radiomics + clinical data model improving relapse estimation in colon cancer. Key variables included fractal features, vascular invasion, and radiomic patterns, which outperformed conventional staging.
Prediction of oncogene mutation status in non-small cell lung cancer
Radiomics-based models offering a non-invasive alternative for determining oncogene mutation status in NSCLC (including EGFR, ALK and KRAS).
Risk stratification in pediatric cancer
Integrating radiomic features with standard clinical and molecular variables enabled the successful and reproducible risk stratification of patients with neuroblastoma, demonstrating a superior stratification compared to the standard-of-care classification system.
From unstructured imaging data to precision medicine decisions
Our platform and integrated tools empower customers to advance their analytical capabilities by connecting imaging data with processed electronic health records (EHRs), facilitating the discovery of novel predictive models and biomarkers. By leveraging QP-Insights' optimized imaging capabilities, you gain a comprehensive, end-to-end solution that seamlessly transitions from data acquisition to meaningful discovery.
Your imaging data optimized to improve success rates in clinical studies
About us
At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions.
Our business model integrates a SaaS platform with partnerships across biopharma, where we jointly develop imaging biomarkers and decision‑support tools that solve high‑value needs and translate into regulatory‑ready, deployable products.
Copyright © 2026 Quibim